Erin Michos, MD 10 months ago
So exciting! #SUMMIT trial, the first #HFpEF trial of incretin therapy with HF clinical outcomes as prespecified primary outcome. And #tirzepatide reduced CV death or worsening HF by significant 38%! Improvement in KCCQ quality of life by 7 pts, wt loss 12%, hsCRP reduction by 35%! #AHA24 #CardioSky